LEXX Lexaria Bioscience Corp.
$3.22▲ +10.27%
Healthcare
Other
After hours
$3.12▼ -3.11%
Oct 27, 5:57 PM ET
Volume 41.8K
Avg Volume (10D) 55.2K
Key Metrics & Fundamentals
Market Cap
$6.78M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.43 - 21.60
% vs 50 MA
-43.95%
% vs 200 MA
-64.54%
RSI-14
44.6
MACD Histogram
+0.2000
Beta (1Y vs SPY)
0.94
Free Cash Flow
-$1.66M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.97M
COGS
$0
Operating Exp
$1.99M
Operating Income
-$1.99M
EBIT
-$1.99M
Pretax Income
-$1.99M
Net Income
-$1.99M
EPS (Diluted)
-1.20
Price & Volume History
Loading chart…
Recent News
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
ACCESS Newswire · Oct 21, 2026 9:25 AM ET
Lexaria Announces Results from Animal Study GLP-1-A26-1
ACCESS Newswire · Oct 15, 2026 9:10 AM ET
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
ACCESS Newswire · Oct 6, 2026 9:10 AM ET
Lexaria Updates Financial Position
ACCESS Newswire · Sep 17, 2026 9:10 AM ET
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
ACCESS Newswire · Sep 9, 2026 4:15 PM ET
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
ACCESS Newswire · Sep 8, 2026 8:00 AM ET
LEXX: Introducing DehydraTECH 3.0
Zacks Small Cap Research · Sep 8, 2026 6:15 AM ET
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
ACCESS Newswire · Sep 4, 2026 9:20 AM ET
Lexaria Receives USD$2.6 Million Tax Rebate Payment
ACCESS Newswire · Sep 1, 2026 9:15 AM ET
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
ACCESS Newswire · Aug 24, 2026 9:10 AM ET
Financial Overview - Income Statement
Quarterly
Feb 2026
See LEXX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.